One connector, four scholarly indexes, real DOIs and legal free PDFs. Works in Claude and ChatGPT.
Paste it into Claude or ChatGPT as a custom connector. 3-day free trial.
Maria J. Corral, Hilde Moyaert, Tiago Fernandes, Monica Escalada, Jezaniah Kira Tena, Rodney R. Walters, Michael R. Stegemann
OBJECTIVE: Bedinvetmab is a canine monoclonal antibody targeting nerve growth factor. This study evaluated the efficacy and safety of bedinvetmab for alleviation of pain associated with osteoarthritis in dogs. STUDY DESIGN: Double-blind, randomized, multicentre, placebo-controlled study. ANIMALS: Client-owned dogs (n = 287) with osteoarthritis. METHODS: , n = 141) administered monthly. After 3 months, 89 bedinvetmab-treated dogs that responded positively based on owner and veterinarian assessments were administered up to six additional doses of bedinvetmab in a single-armed open-label continuation phase. The primary efficacy end point was treatment success based on the owner-assessed canine brief pain inventory (CBPI) on day 28. Treatment success was defined as ≥ 1 reduction in pain severity score (0-10) and ≥ 2 in pain interference score (0-10). RESULTS: Percentage treatment success was significantly greater in the bedinvetmab group than in the placebo group from day 7 through all assessed time points (p ≤ 0.0025). On day 28, 43.5% of dogs achieved treatment success with bedinvetmab compared with placebo (16.9%) (p = 0.0017). Treatment success continued through days 56 (50.8%) and 84 (48.2%) in the bedinvetmab group and was < 25% in the placebo group at all time points. Sustained efficacy was demonstrated in the continuation phase. Adverse health events occurred at similar frequencies in both groups. They were considered typical for a population of dogs with osteoarthritis and not related to study treatment. Treatment with bedinvetmab demonstrated a significant effect on all three components of CBPI-pain interference, pain severity, quality of life. CONCLUSIONS AND CLINICAL RELEVANCE: for alleviation of pain associated with canine osteoarthritis.
Formatted from the source metadata, not typed by hand. For a whole reference list, use the citation generator or ask your assistant through Find Research.
Corral, M. J., Moyaert, H., Fernandes, T., Escalada, M., Tena, J. K., Walters, R. R., & Stegemann, M. R. (2021). A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis. Veterinary Anaesthesia and Analgesia, 48(6), 943–955. https://doi.org/10.1016/j.vaa.2021.08.001
Corral, Maria J., et al. "A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis." Veterinary Anaesthesia and Analgesia, vol. 48, no. 6, 2021, pp. 943–955, https://doi.org/10.1016/j.vaa.2021.08.001.
Corral, Maria J., Hilde Moyaert, Tiago Fernandes, Monica Escalada, Jezaniah Kira Tena, Rodney R. Walters, and Michael R. Stegemann. "A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis." Veterinary Anaesthesia and Analgesia 48, no. 6 (2021): 943–955. https://doi.org/10.1016/j.vaa.2021.08.001.
Corral M. J., Moyaert H., Fernandes T. [и др.] A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis // Veterinary Anaesthesia and Analgesia. — 2021. — Vol. 48, № 6. — P. 943–955. — URL: https://doi.org/10.1016/j.vaa.2021.08.001
@article{corral2021prospective,
title = {{A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis}},
author = {Maria J. Corral and Hilde Moyaert and Tiago Fernandes and Monica Escalada and Jezaniah Kira Tena and Rodney R. Walters and Michael R. Stegemann},
journal = {Veterinary Anaesthesia and Analgesia},
year = {2021},
volume = {48},
number = {6},
pages = {943--955},
doi = {10.1016/j.vaa.2021.08.001},
url = {https://doi.org/10.1016/j.vaa.2021.08.001}
}TY - JOUR AU - Corral, Maria J. AU - Moyaert, Hilde AU - Fernandes, Tiago AU - Escalada, Monica AU - Tena, Jezaniah Kira AU - Walters, Rodney R. AU - Stegemann, Michael R. TI - A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis JO - Veterinary Anaesthesia and Analgesia VL - 48 IS - 6 SP - 943 EP - 955 PY - 2021 DA - 2021/08/22 DO - 10.1016/j.vaa.2021.08.001 UR - https://doi.org/10.1016/j.vaa.2021.08.001 ER -
Add Find Research to Claude or ChatGPT and ask in plain language. The assistant reads this record, finds the papers around it and cites only what it actually found:
Setup takes about a minute: add the connector, then start the free trial.
Record from OpenAlex; open-access location from Unpaywall and the indexes. Find Research links only to legal copies.